trial · primary record
Acalabrutinib
Diffuse Large B-Cell Lymphoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 80 |
| Primary completion | 2029-04-22 |
| Primary endpoint | Percentage of patients with Grade 3 to 4 treatment emergent adverse events (TEAEs) |
| Registry ID | NCT05952024 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:44:40.806Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05952024
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Acalabrutinib · approval
- Acalabrutinib · compound